Start-Up Spotlight: Miach’s BEAR Implant Helps Body Repair Torn ACL
Miach Orthopedics expects to soon earn US FDA de novo clearance for its Bridge-Enhanced ACL Repair (BEAR) technology as an alternative to conventional anterior cruciate ligament reconstruction surgery. Trials have shown BEAR helps restore torn ACLs to normal strength and function.
You may also be interested in...
Medtech Insight spoke with Martha Shadan, CEO of Miach Orthopaedics, about the company’s marketing efforts for its US FDA-cleared BEAR implant for treating anterior cruciate ligament (ACL) tears, ongoing clinical trials, plans for the rest of the year, and highlights from the AAOS 2022 event.
The Bridge-Enhanced ACL Repair Implant de novo-cleared by the FDA addresses a common football injury suffered by US athletes.
The global market for arthroscopy products and sports medicine devices is expected to reach $9bn by 2023, a CAGR of 4.2%, driven by technological advancements, improved surgical techniques and a growing number of surgeons performing minimally invasive surgeries. With hip fixation devices expected to see double-digit growth by 2023, we'll take a closer look at recent technological innovations driving this sector, the key players, and also offer viewpoints from four orthopedic surgeons on what is driving their decision to adopt technologies. We'll also highlight the latest arthroscopes on the market, which is the fastest-growing segment in the global arthroscopy products market.